Bayer AG adds a brand to its US OTC allergy remedy lineup as the Food and Drug Administration adds a first-in-class ingredient to the products it has approved for nonprescription sales with a partial OTC switch of azelastine hydrochloride nasal spray, 0.15%.
The FDA’s Center for Drug Evaluation and Research on 17 June announced approval of an application Bayer Healthcare LLC submitted for a nasal antihistamine branded Astepro Allergy and indicated at once- or twice-daily dosing for seasonal allergic rhinitis in adults and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?